Investors in Genetics

Stonehaven Incubate looks at disruptive technologies in human health and identifies the unique opportunities for animals. So we shake hands with the innovators and build strategies for new, stand-alone animal health companies. We find experienced management teams. We source the capital required. In fact, we leave no stone unturned in our quest to bring human innovations to animal health.

Venture Catalysts is a company focused on commercialization of technologies through entrepreneurship. By supporting visionary researchers and entrepreneurs releasing the full potential of their technologies, the company acts as a catalyst on the development of new technology–based ventures

Venture Catalysts is a company focused on commercialization of technologies through entrepreneurship. By supporting visionary researchers and entrepreneurs releasing the full potential of their technologies, the company acts as a catalyst on the development of new technology–based ventures

4BIO Capital is a specialized fund dedicated to investing in and developing early-stage advanced therapy companies. With a strategic focus on the healthcare sector, particularly in advanced therapies, 4BIO Capital supports innovative companies that are pioneering breakthrough treatments and technologies. By providing capital, strategic guidance, and industry expertise, 4BIO Capital aims to accelerate the development and commercialization of transformative therapies, contributing to advancements in healthcare and improving patient outcomes globally.

Phystech Ventures is an early-stage venture capital firm specializing in deep technology (deeptech) investments. With a focus on next-generation computing, life sciences, energy, mobility, and space sectors, Phystech Ventures identifies and supports startups at the forefront of technological innovation. The firm provides critical funding and strategic support to help these companies develop breakthrough technologies and scale their operations. Phystech Ventures' investment strategy is driven by a commitment to advancing transformative innovations that address global challenges and drive sustainable growth. For entrepreneurs seeking early-stage investment in deeptech sectors, Phystech Ventures offers expertise and resources to propel innovation forward.

We support early-stage biotech and longevity-focused founders that are changing the world. We help these companies gain industrial momentum, raise capital, and shape the future of biotech. Our approach is based on growing the whole ecosystem. We fund companies in complementary industrial sectors, empowering us to build a broad community of biotech innovators that can exchange their expertise and build on each other's successes.

Ahren is a deep tech and deep science investment firm set up by Alice Newcombe-Ellis alongside co-Founding Science Partners. Together, these Founders created companies and/or technologies that are today valued in excess of $100BN combined. The firm was established from first principles with a mission to be disruptive as an investment institution, with a new model – genuine partnership between the creators of deep technology and deep science, and commercially active, long-term capital, to harness tremendous global talent and build and exponentially accelerate the next generation of great enterprises. Ahren’s Portfolio companies include AI21 Labs, Graphcore, Zapata Computing, ZOE, Phaidra, Heirloom Carbon, and Bicycle Therapeutics among others. Ahren has >$800M AUM and has team members in Cambridge (UK), London, and Boston.

TEAL Impact VC is an early-stage, impact-driven investment firm focused on Europe and the UK, seeking the best combination of team, product, and impact. They support companies from early to growth stages, enhancing their business models and measuring impact. Known for being founder-friendly, lightning fast, hands-on, and collaborative, TEAL Impact VC leverages a diverse and experienced team to drive success and impactful results.